Advertisement
Advertisement

ENTA

ENTA logo

Enanta Pharmaceuticals, Inc

12.88
USD
Sponsored
-0.02
-0.13%
Jan 30, 16:00 UTC -5
Closed
exchange

After-Market

12.91

+0.03
+0.21%

ENTA Earnings Reports

Positive Surprise Ratio

ENTA beat 25 of 39 last estimates.

64%

Next Report

Date of Next Report
Feb 09, 2026
Estimate for Q1 26 (Revenue/ EPS)
$16.46M
/
-$0.82
Implied change from Q4 25 (Revenue/ EPS)
+8.84%
/
-5.75%
Implied change from Q1 25 (Revenue/ EPS)
-2.93%
/
-21.90%

Enanta Pharmaceuticals, Inc earnings per share and revenue

On Nov 17, 2025, ENTA reported earnings of -0.87 USD per share (EPS) for Q4 25, beating the estimate of -1.04 USD, resulting in a 16.46% surprise. Revenue reached 15.13 million, compared to an expected 16.28 million, with a -7.07% difference. The market reacted with a -3.59% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of -0.82 USD, with revenue projected to reach 16.46 million USD, implying an decrease of -5.75% EPS, and increase of 8.84% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
For Q4 2025, Enanta Pharmaceuticals, Inc reported EPS of -$0.87, beating estimates by 16.46%, and revenue of $15.13M, -7.07% below expectations.
The stock price moved down -3.59%, changed from $12.82 before the earnings release to $12.36 the day after.
The next earning report is scheduled for Feb 09, 2026.
Based on 6 analysts, Enanta Pharmaceuticals, Inc is expected to report EPS of -$0.82 and revenue of $16.46M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement